ArticlePharmacoEconomics - open2026

Cost-Utility Analysis of Faricimab Versus Aflibercept in Treating Neovascular Age-Related Macular Degeneration (nAMD) in the United States.

Ahmead Baljoon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.